Huons Co., Ltd. (243070.KQ)
KRW 27400.0
(8.3%)
KRW 27400.0
(8.3%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 73.9 Billion KRW | -3.22% |
| 2022 | 76.36 Billion KRW | 242.49% |
| 2021 | 22.29 Billion KRW | -69.81% |
| 2020 | 73.87 Billion KRW | 5556.48% |
| 2019 | -1.35 Billion KRW | -245.49% |
| 2018 | 930.53 Million KRW | 127.53% |
| 2017 | -3.38 Billion KRW | -117.24% |
| 2016 | 19.61 Billion KRW | 0.0% |
| 2014 | -10.37 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 61.28 Billion KRW | -17.09% |
| 2024 Q2 | 92.63 Billion KRW | 51.17% |
| 2023 Q4 | 73.9 Billion KRW | 81.03% |
| 2023 FY | 73.9 Billion KRW | -3.22% |
| 2023 Q1 | 32.98 Billion KRW | -56.81% |
| 2023 Q2 | 43.92 Billion KRW | 33.16% |
| 2023 Q3 | 40.82 Billion KRW | -7.05% |
| 2022 Q2 | 73.24 Billion KRW | 65.38% |
| 2022 Q1 | 44.29 Billion KRW | 98.63% |
| 2022 FY | 76.36 Billion KRW | 242.49% |
| 2022 Q4 | 76.36 Billion KRW | 21.36% |
| 2022 Q3 | 62.92 Billion KRW | -14.09% |
| 2021 Q2 | 39.77 Billion KRW | -34.13% |
| 2021 Q4 | 22.29 Billion KRW | -62.1% |
| 2021 Q1 | 60.38 Billion KRW | -16.94% |
| 2021 FY | 22.29 Billion KRW | -69.81% |
| 2021 Q3 | 58.83 Billion KRW | 47.93% |
| 2020 FY | 73.87 Billion KRW | 5556.48% |
| 2020 Q4 | 72.69 Billion KRW | 122.07% |
| 2020 Q3 | 32.73 Billion KRW | 43.91% |
| 2020 Q2 | 22.74 Billion KRW | 202.49% |
| 2020 Q1 | -22.19 Billion KRW | -905.16% |
| 2019 FY | -1.35 Billion KRW | -245.49% |
| 2019 Q1 | -6.39 Billion KRW | -787.02% |
| 2019 Q4 | -2.2 Billion KRW | 20.99% |
| 2019 Q3 | -2.79 Billion KRW | -91.9% |
| 2019 Q2 | -1.45 Billion KRW | 77.22% |
| 2018 FY | 930.53 Million KRW | 127.53% |
| 2018 Q3 | 5.45 Billion KRW | 405.67% |
| 2018 Q2 | -1.78 Billion KRW | 84.52% |
| 2018 Q4 | 930.53 Million KRW | -82.93% |
| 2018 Q1 | -11.51 Billion KRW | -240.76% |
| 2017 Q2 | 5.84 Billion KRW | -28.51% |
| 2017 Q4 | -3.38 Billion KRW | -247.94% |
| 2017 FY | -3.38 Billion KRW | -117.24% |
| 2017 Q1 | 8.17 Billion KRW | -58.31% |
| 2017 Q3 | 2.28 Billion KRW | -60.91% |
| 2016 Q3 | 26.1 Billion KRW | 0.0% |
| 2016 Q4 | 19.61 Billion KRW | -24.89% |
| 2016 FY | 19.61 Billion KRW | 0.0% |
| 2014 FY | -10.37 Billion KRW | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 18.96 Billion KRW | -289.795% |
| CMG Pharmaceutical Co., Ltd. | 18.78 Billion KRW | -293.469% |
| Celltrion Pharm, Inc. | 142.81 Billion KRW | 48.248% |
| Huons Global Co., Ltd. | 13.26 Billion KRW | -457.183% |
| DongKook Pharmaceutical Co., Ltd. | 44.19 Billion KRW | -67.239% |
| Enzychem Lifesciences Corporation | -9.81 Billion KRW | 853.164% |
| Humedix Co., Ltd. | -77.54 Billion KRW | 195.312% |
| Boditech Med Inc. | -31.92 Billion KRW | 331.501% |
| EuBiologics Co., Ltd. | 4.88 Billion KRW | -1414.082% |
| FutureChem Co.,Ltd | -4.93 Billion KRW | 1598.996% |
| BNC Korea Co., Ltd. | -67.65 Billion KRW | 209.252% |
| AptaBio Therapeutics Inc. | -12.08 Billion KRW | 711.722% |